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ECONOMIC BURDEN OF COPD
Chronic obstructive pulmonary disease is
one of the leading “prosperity diseases”
worldwide. Pooled global prevalence rates
based on clinical assessments and spirom-
etry ranged from 7.6 to 8.9%, reported in
a sound meta-analytical study design (1).
It has far reaching consequences, not only
for an affected patient’s health but also
for the entire national health systems (2).
These refer to the substantial work load for
the medical facilities due to chronic clin-
ical course of illness and modest success
of available treatment approaches. COPD
attributable resource utilization patterns
are particularly substantial if large univer-
sity tertiary care hospitals, specialist clin-
ics, and intensive care units are observed
(3). According to most of published evi-
dence the key cost driver are periodic exac-
erbations followed by intensive care unit
admissions and episodes of infectious com-
plications (4). Among major cost domains,
physician consultations and surgery dom-
inate in high-income settings. Unlike in
the West, within the most of South East-
ern European region, COPD medical care
is still dominated with acquisition costs of
pharmaceuticals and oxygen (5) and imag-
ing diagnostics (6). Outpacing of indirect
productivity-related opportunity costs by
the direct costs of in- and outpatient med-
ical care is common to this region due
to substantially lower wages of physicians
and nursing staff (7). Apart from direct
costs of COPD, mainly constituted from
the resources consumed in the health care
process, including costs of ambulatory care,
drug treatment, hospital care, rehabilita-
tion, and long-term home care, there are
substantial indirect costs of COPD, which
are incurred by productivity losses, prema-
ture retirement, and premature mortality
from this disease. The indirect costs for
premature mortality are being calculated
through human capital approach, with the
life years lost up to the age of 65 multiplied
by the gross annual income. An insight
into the economic reality of SEE region,
particularly Serbia, with average wages sig-
nificantly lower than in countries of the
Western Europe, but at the same time with
high unemployment rates in younger age
groups, where some 50% of the work-
ing population is currently outside of the
workforce (8), being in their most produc-
tive decades of life but at the same time
most prevalent tobacco users, makes indi-
rect cost of COPD in SEE region very diffi-
cult to calculate or even predict, but clearly
shows significant magnitude of this bur-
den in present years, and probable rise of
these costs in the future. Intangible costs
are not convertible into monetary terms
and units, they are specifically related to
the distress and suffering, which is caused
by the disease. General lack of insight into
patients’ perception of the disease and lim-
itation and incapability, which it imposes,
while healthcare workers are being focused
mainly on physical burden of the dis-
ease, with very few patients being provided
with structurised psychosocial aid in the
attempt to overcome significant yet under-
estimated mental and emotional burden of
the disease, makes these costs impossible to
predict and foresee.
AN EXAMPLE OF SERBIA’S HEALTH
REFORMS
Serbia as the largest Western Balkans
upper-middle income market began health
reforms one decade later than most tran-
sitional countries of SEE region (9, 10).
After dynamic 2000–2007 GDP increase
and overall development, the issue of long-
term sustainability of its health system
financing became hot topic under the first
strike of global recession (11). Large part of
almost unbearable economic burden was
attributable to the major prosperity dis-
eases including pulmonary diseases (12).
The unique common weakness revealed
by all of these pioneering cost-of-illness
assessments in the Balkans region was poor
health system responsiveness to popula-
tion needs together with overextended hos-
pital budgets and accumulating of pub-
lic depth generated by the national health
insurance fund (13). An occurrence of
catastrophic household expenditure trig-
gered by severe illness, sinking entire fam-
ilies into poverty is still prevalent within
the society (14). Expensive medical tech-
nologies, which were denied reimburse-
ment, remained mostly unaffordable to the
ordinary citizens (15).
CONSEQUENCES OF COPD RELATIVE TO
POPULATION AGING AND COMORBID
DISORDERS
Populations across Eastern Europe and the
Balkans are aging even more rapidly than
their Western European counterparts. This
population aging is likely to further con-
strain already limited resource allocation
in health care (16). This happens mostly
due to dwindling base of employed tax
payers in their most productive life time
combined with increased proportion of the
elderly. Demand for medical services by
the retired citizens is significantly higher
compared to working, younger age groups
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and this is particularly the case within the
last year of life (17). Substantial impact
of age to the COPD costs of care was
already claimed in literature. Clinical sever-
ity of disease according to the Global
initiative for chronic Obstructive Lung Dis-
ease (GOLD) classification, clearly corre-
lated with resource use and costs of hospital
and outpatient care (18).
In an exploration of long-term phar-
maceutical market transformation trends
in Western Balkans, it has been observed
that agents used to treat COPD exhibited
prominent rise in market share during the
past decade. Reported value based turnover
of medicines intended to treat respiratory
disorders grew from C 17,090,000 in 2004
to the C 46,500,000 in 2012 (19). It is
a paradox that during same 9 years unit
drug consumption in terms of defined daily
doses DDD/1000 inhabitants/day actually
fell from 164.55 in 2004 to 50.55 level
in 2012 [according to Anatomical Thera-
peutic Chemical (ATC) classification (“R”
ground code group)] (20). Explanation
for this shift in Balkan pharmaceutical
markets should be looked within stronger
brand penetration and modest success of
generic pharmaceuticals in many therapeu-
tic areas (21). COPD-related prescription
and dispensing of β-adrenergic prepara-
tions in combination with inhalatory cor-
ticosteroids (“R03AK” ATC code group)
were reported record breaking fivefold
increase from C 2,682,320 in 2004 toward
C 11,761,775 in 2012 based on latest offi-
cial release by the National Medicines and
Medicinal Device Agency of Serbia (22).
Recent dissertation conducted on health
economics of community acquired pneu-
monia (CAP), proved clear proof of sub-
stantial COPD comorbidity impact to the
overall costs of medical care. While ordi-
nary CAP clinical cases incurred on aver-
age C 717 costs in a 1 month time hori-
zon while the ones suffering from COPD
and CAP incurred C 970 monthly costs of
inpatient care (23).
PROPOSED MEASURES TO TACKLE THE
CHALLENGES LYING AHEAD
Although COPD prevalence and inci-
dence seem to be steadily slowing down
in some parts of the European region,
this might not be the case with mor-
tality rates. Unfortunately, COPD will
most likely be the third leading cause
of death worldwide and the fifth leading
cause of years lost through early mor-
tality or handicap (disability-adjusted life
years) in 2020, which is far worse land-
scape compared to 1990 (24). So far seri-
ous policy initiatives to combat decreased
longevity and quality of life caused by
COPD have been taken both by WHO
and the European COPD Coalition (ECC)
(25). Orchestrated supranational efforts to
increase research investment in the thera-
peutic options for COPD were proposed
within the Horizon 2020 framework as
well (26).
Broad forecasts on COPD for the South
Eastern European region may be signifi-
cantly less optimistic compared to the tra-
ditional EU15 economies (see Table 1).
Some underlying reasons are strong pop-
ular affection toward smoking tobacco
among adolescents (27, 28) and inef-
ficiencies of anti-tobacco public health
campaigns and policies (29). Environmen-
tal pollution plays less significant role due
to shutting down of most heavy industries
in former socialist countries (30) due to
socioeconomic transition as well as their
lack of global competitiveness (31). Popu-
lar opinion on tobacco is gradually begin-
ning to change but this is likely to be
a lengthy process. Additional obstacles to
this tobacco reduction process seem to be
traditionally high prevalence of tobacco
smoking habit in Balkan countries such
as Bulgaria (32) and FYR Macedonia (33)
and heavy investment of global multi-
national tobacco manufacturers in Serbia
and Turkey in particular (34). Essential
revenues provided to the local govern-
ments by taxation of tobacco sales both
to the industry and the consumers is still
too important to the regional economies,
still outside EU, such as Western Balkans
and Turkey. This fact makes tobacco con-
trol policies currently in place less suc-
cessful. Opposingly, promising trend of
decreasing tobacco consumption is clearly
visible in the OECD economies such
as Greece (35), Slovenia, Hungary, and
Cyprus where smoking free legislation,
higher taxes on cigarettes, and facilitated
access to medicines used to treat nico-
tine addiction are being applied for a
number of years in line with the EU
health priority targets (36). According to
combined tobacco control score (TCS),
most countries of South Eastern European
region obtained <50 grades with the excep-
tions of Ukraine and Turkey. Interestingly,
unsatisfactory and weak tobacco con-
trol policies remain in place in a num-
ber of traditional high-income European
economies.
Containing epidemiological burden of
COPD in the Balkans, while providing
equitable and affordable medical care for
patients will demand surmounting efforts
from local communities. Economic conse-
quences in terms of illness attributed lost
productivity are huge and due to ongoing
upward economic developments in the area
likely to increase further. Current national
capacities in SEE health care provision
remain insufficient, not only in terms of
professional staff but also in terms of spe-
cialized clinics and rehabilitation facilities,
which are still scarce across the region (37).
Through the course of past decades, his-
torical network of facilities created to com-
bat tuberculosis was seriously downsized
due to successes of innovative vaccines
and antibiotics. Another important issue is
strong concentration of clinical physicians
and nurses in urban cores, leaving rural
areas underserved (38).
Far reaching potentially successful strat-
egy to combat COPD in South Eastern
Europe would have several distinct fea-
tures. Such effort should be supranational
and should contain key priorities defined
within common EU policy on COPD
(39). It would have to include peculiari-
ties of local public health and clinical set-
tings, which were already proven to affect
resource use and outcomes of COPD med-
ical care (40). Major measures assume
prevention of smoking among youth and
controlling environmental pollution pri-
marily in large cities. Timely detection
of illness by broadly targeted diagnostic
screenings could allow more efficient treat-
ment and preserving clinical evolution in
its early stages. Evidence based allocation,
favoring implementation of cost-effective
diagnostic and treatment protocols would
help to contain cost without significant
adverse influence to the quality of care.
Such a complex approach could allow
larger portion of local communities to be
taken care for, particularly among the poor
and underserved citizens.
Although the quantification of the
direct health care costs of COPD as well
as indirect and intangible costs in these
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Table 1 | Ground indicators on respiratory disorders, tobacco consumption, and health expenditures in SEE 1980–2010.
Country AL BA BG HR CY GR HU MN MD RO RS SK SI MK TR UA
SDR, bronchi-
tis/emphysema/asthma,
all ages, per
100,000 – 1980
26.081987 36.771985 41.91 27.861985 12.892004 20.64 62.15 1.72000 20.11981 71.71 28.671998 31.971986 14.741985 40.251991 N/A 26.571981
SDR, bronchi-
tis/emphysema/asthma,
all ages, per
100,000 – 2010
13.072004 15.332011 10.45 21.06 9.31 0.17 31.1 0.122009 42.3 20.5 23.04 13.09 12.2 18.74 35.83 31.162004
SDR, selected
smoking-related causes,
per 100,000 – 1980
262.811987 269.461985 544.43 353.881985 158.332004 292.22 566.24 243.382000 844.851996 461.93 382.431998 440.381992 347.761985 335.441991 N/A 637.251991
SDR, selected
smoking-related causes,
per 100,000 – 2010
324.092004 237.582011 345.25 349.9 128.09 183.07 425.16 180.622009 762.36 427.69 332.47 416.46 185.02 331.21 232.04 774.792004
Hospital discharges,
respiratory system
diseases, per
100,000 – 1980
1954.461989 850.83 2743.52 1351.221981 773.5 1193.82 1854.341992 1678.871988 3830.1 3089.9 812.192000 1958.951991 1721.4 970.651983 329.85 4930.78
Hospital discharges,
respiratory system
diseases, per
100,000 – 2010
1331.93 855.921989 3098.79 998.13 599.762008 1536.892007 1685.35 1275.22 2467.71 2817.71 1106.06 1471.01 1410.742009 1863.55 1781.6 3704.3
Prevalence of chronic
obstructive pulmonary
disease (%) – 1980
0.151994 3.14 2.6 0.411981 N/A 0.35 0.121988 N/A 1.31991 0.491989 N/A 1.021994 N/A 0.171983 N/A 2.761996
Prevalence of chronic
obstructive pulmonary
disease (%) – 2010
0.21 1.56 2.252000 0.14 N/A 0.242008 1.47 N/A N/A 1.47 N/A 1.68 N/A 0.382007 N/A 3.94
Number of cases of
chronic obstructive
pulmonary
disease – 1980
48701994 128449 230335 187451981 N/A 34117 372781990 N/A 568781991 1138141989 N/A 545451994 N/A 33591983 N/A 14036401996
Number of cases of
chronic obstructive
pulmonary
disease – 2010
6874 59968 1841672000 6200 N/A 265952008 147480 N/A N/A 315437 N/A 91023 N/A 77372007 N/A 1799851
% Of regular daily
smokers in the
population, age
15+ – 1980
29.51990 37.62002 31.41986 32.61995 23.92003 461991 441992 N/A 192000 25.91989 332000 24.41992 341988 N/A 441988 401990
% Of regular daily
smokers in the
population, age
15+ – 2010
39 14.3 39.72007 27.42003 26.52008 31.92009 31.42009 32.72008 27.12006 26.72011 26.22006 19.42009 19.22012 361999 25.4 23.3
Number cigarettes
consumed per person
per year – 1980
436.191996 820.821997 1880.95 21671992 N/A 2271.4 2652.39 N/A N/A 1347.071991 N/A 1715.051993 2500.541996 2143.111996 1167.44 N/A
(Continued)
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Table 1 | Continued
Country AL BA BG HR CY GR HU MN MD RO RS SK SI MK TR UA
Number cigarettes
consumed per person
per year – 2010
744.062000 1244.012000 2792.62000 1736.682000 N/A 3200.492004 2151.412000 N/A N/A 1392.631997 N/A 1230.42000 2232.862000 1794.362000 1547.841998 10272000
Sulfur dioxide emissions,
kg per capita per
year – 1980
N/A 107.191990 231.34 32.72 N/A 41.48 152.46 N/A 76.78 47.52 N/A 156.49 123.41 N/A 4.59 77.14
Sulfur dioxide emissions,
kg per capita per
year – 2010
N/A N/A 104.772000 15.982000 N/A 50.012000 53.862000 N/A 31.612000 40.121994 N/A 38.882000 13.572000 52.31998 15.492000 46.912000
Average annual
concentration of sulfur
dioxide (SO2) in capital,
µg/m3 – 1980
N/A 18.42002 27.41998 N/A N/A 22.21997 41.61997 N/A N/A N/A 58.62003 25.41997 35.41997 27.31997 N/A N/A
Average annual
concentration of sulfur
dioxide (SO2) in capital,
µg/m3 – 2010
38.52009 35.1 9.4 N/A N/A 5.72008 6.7 N/A N/A 15 37.8 19.5 22008 1.3 12.6 N/A
Average annual
concentration of
particulate matter
<10µm (PM10) in the
capital, µg/m3 – 1980
N/A N/A 20.42000 N/A N/A 34.72001 352003 N/A N/A N/A 52.72004 36.51999 30.92002 N/A N/A N/A
Average annual
concentration of
particulate matter
<10µm (PM10) in the
capital, µg/m3 – 2010
22.62009 48.5 48.4 N/A N/A 30.42007 31.9 N/A N/A 35.4 23.1 26.6 29.42009 N/A 59.5 N/A
Average annual
concentration of nitrogen
dioxide (NO2) in capital,
µg/m3 – 1980
N/A 272002 39.72003 N/A N/A 50.81997 53.21997 N/A N/A N/A 40.22003 34.31997 31.62002 N/A N/A N/A
Average annual
concentration of nitrogen
dioxide (NO2) in capital,
µg/m3 – 2010
N/A 25.7 31.3 N/A N/A 42.42008 28.1 N/A N/A 20.52011 27.9 13.3 34.7 152009 N/A N/A
Average annual
concentration of ozone
(O3) in the capital,
µg/m3 – 1980
N/A 68.42006 4.41999 N/A N/A 75.81997 691997 N/A N/A N/A 65.42004 721998 661998 N/A N/A N/A
Average annual
concentration of ozone
(O3) in the capital,
µg/m3 – 2010
N/A 53.6 65.4 N/A N/A 88.62008 73.72009 N/A N/A 57.7 71.22011 71.6 63.7 N/A N/A N/A
Total health expenditure,
PPP$ per capita, WHO
estimates – 1980
97.61995 128.441955 290.221995 546.041995 722.761995 1263.11995 656.741995 445.181995 115.121995 183.441995 259.861995 503.81995 969.41995 421.41995 174.121995 246.561995
Total health expenditure,
PPP$ per capita, WHO
estimates – 2010
481.9 833.74 1053.1 1461.7 2221.68 2584.6 1653.88 947.86 369.66 880.94 1183.44 2088.18 2366.4 772.02 1071.54 520.44
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countries is very difficult, it is clear that
pulmonary specialists across the South
Eastern Europe region are challenged to
increase their efforts to reduce the men-
ace of smoking and to put in additional
efforts in creation of new strategies aimed
at early diagnostics. The estimation of total
health care costs can therefore only be a
first step in assessing the overall impact
of COPD burden in South East Europe
region. Further studies on the economic
burden of COPD, including the perspec-
tive of mostly underestimated indirect and
intangible costs within the region will be
needed to prove and justify the prevention
and early diagnostics efforts and devel-
opment of new strategies of reduction
of both financial and non-financial bur-
den of disease. Many policy makers are
starting to realize that a more robust evi-
dence base is needed in order to make
informed decisions on resource allocation.
In light of current weaknesses of regional
health financing, funding the quest for
knowledge of the local cost drivers of
key clinical conditions represents a valu-
able investment in the future of emerging
markets (41).
COPD with its multimillion patient
population in the SEE region should be
regarded as one of the high-profile pol-
icy issues on the agenda of national
health ministries and governmental agen-
cies. Future of these patients remains par-
ticularly unpredictable among the small
Western Balkan economies approaching
EU membership.
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